235 related articles for article (PubMed ID: 29501383)
1. Is pathological complete response after a trimodality therapy, a predictive factor of long-term survival in locally-advanced esophageal cancer? Results of a retrospective monocentric study.
Francoual J; Lebreton G; Bazille C; Galais MP; Dupont B; Alves A; Lubrano J; Morello R; Menahem B
J Visc Surg; 2018 Oct; 155(5):365-374. PubMed ID: 29501383
[TBL] [Abstract][Full Text] [Related]
2. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
[TBL] [Abstract][Full Text] [Related]
3. Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
Kim MK; Cho KJ; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Song HJ; Ryu JS; Kim SB
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):115-21. PubMed ID: 19251379
[TBL] [Abstract][Full Text] [Related]
4. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
5. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience.
Blum Murphy M; Xiao L; Patel VR; Maru DM; Correa AM; G Amlashi F; Liao Z; Komaki R; Lin SH; Skinner HD; Vaporciyan A; Walsh GL; Swisher SG; Sepesi B; Lee JH; Bhutani MS; Weston B; Hofstetter WL; Ajani JA
Cancer; 2017 Nov; 123(21):4106-4113. PubMed ID: 28885712
[TBL] [Abstract][Full Text] [Related]
6. [Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].
Ruffier-Loubière A; Janoray G; Chapet S; de Calan L; Dumont P; Dorval É; Orain I; Calais G
Cancer Radiother; 2015 Aug; 19(5):322-30. PubMed ID: 26215366
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
[TBL] [Abstract][Full Text] [Related]
8. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
[TBL] [Abstract][Full Text] [Related]
9. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
[TBL] [Abstract][Full Text] [Related]
10. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
[TBL] [Abstract][Full Text] [Related]
12. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
[TBL] [Abstract][Full Text] [Related]
13. Trimodality treatment versus surgery alone for esophageal cancer. A stratified analysis with minimally invasive pretreatment staging.
Jiao X; Sonett J; Gamliel Z; Doyle A; Schuetz J; Greenwald B; Suntharalingam M; Krasna MJ
J Cardiovasc Surg (Torino); 2002 Aug; 43(4):531-7. PubMed ID: 12124569
[TBL] [Abstract][Full Text] [Related]
14. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
[TBL] [Abstract][Full Text] [Related]
16. The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
Kim GJ; Koshy M; Hanlon AL; Horiba MN; Edelman MJ; Burrows WM; Battafarano RJ; Suntharalingam M
Am J Clin Oncol; 2016 Apr; 39(2):136-41. PubMed ID: 24487417
[TBL] [Abstract][Full Text] [Related]
17. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
18. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
19. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database.
Vlacich G; Samson PP; Perkins SM; Roach MC; Parikh PJ; Bradley JD; Lockhart AC; Puri V; Meyers BF; Kozower B; Robinson CG
Cancer Med; 2017 Dec; 6(12):2886-2896. PubMed ID: 29139215
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]